Rilonacept (Interleukin-1 Trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results of the presurge-1 trial
Arthritis Care & Research ,  Clinical Article

Schumacher HR et al. – Rilonacept markedly reduced the occurrence of gout flares (GFs) associated with initiation of uric acid–lowering therapy (ULT). The efficacy and safety profile suggest that rilonacept may have the potential to improve long–term disease control for some patients by improving adherence to ULT therapy by reducing flares during the first months after ULT initiation.

Methods
  • 241 adult patients with gout, ≥2 GFs within the past year, and serum urate ≥7.5 mg/dL were initiated on allopurinol 300 mg daily and randomly allocated 1:1:1 to receive 16 once–weekly subcutaneous injections of placebo, rilonacept 80mg (R80), or rilonacept 160mg (R160), with a double (loading) dose on Day 1.
  • Allopurinol was titrated to achieve serum urate <6.0 mg/dL.
  • The study was powered for the primary efficacy endpoint, number of GFs per patient through Week 16.

Results
  • More patients in the rilonacept groups (R80 80.0%, R160 86.4%) completed the study than in the placebo group (72.5%)(P<0.05 for R160 versus placebo).
  • Over 16 weeks, mean number of GFs per patient was significantly reduced by rilonacept treatment (placebo 1.06,R80 0.29 [P<0.001], R160 0.21 [P<0.001]).
  • Significantly lower proportions of patients reported 1 or more GFs with R80 (18.8%) and R160 (16.3%) relative to placebo (46.8%) (both P<0.001).
  • Except for injection site reactions (1.3% placebo vs 8.8% R80 [P=0.0635, post–hoc analysis] and 19.8% R160 [P=0.0001, post–hoc analysis]), the incidence of adverse events was generally balanced among treatment groups.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Internal Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

<

Most Popular Internal Medicine Articles

Indexed Journals in Internal Medicine: New England Journal of Medicine, The Lancet, Archives of Internal Medicinemore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List